REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Phosphorus Containing Other Than Solely As Part Of An Inorganic Ion In An Addition Salt Doai > Nitrogen Containing Hetero Ring > Hetero Ring Is Six-membered And Includes Only One Ring Nitrogen Hetero Ring Is Six-membered And Includes Only One Ring NitrogenHetero Ring Is Six-membered And Includes Only One Ring Nitrogen patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/18/07 - 20070015734 - Mao-b inhibitors useful for treating obesity that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance). ... 01/11/07 - 20070010492 - Composition and method for reducing homocysteine caused by drugs containing methyl compounds This invention relates to a method and composition of limiting homocysteine. The composition consists of a problematic drug which specifically contains at least one CH3 methyl group at one or more end(s) of its chemical structure. This problematic drug is combined in an embodiment with one or more antidotal cofactors ... 01/04/07 - 20070004681 - Methods for treating arthritic conditions The present invention relates to a method for eliciting a disease modifying effect on an arthritic condition in a mammal which comprises administering to the mammal a therapeutically effective amount of an anti-resorptive compound. The present invention also relates to method for eliciting a disease modifying effect on subchondral bone ... 12/14/06 - 20060281714 - Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss This invention relates to pharmaceutical preparations comprising certain types of bisphosphonates and certain types of Cathepsin K inhibitors, in particular in the prevention and treatment of bone metastases, tumor-induced hypercalcemia, tumor growth, tumor-induced bone loss and bone loss diseases such as osteoporosis or cancer-therapy-induced bone loss ... 12/14/06 - 20060281713 - 5-thiopiperdinyl prostaglandin e analogs or a derivative thereof, or a pharmaceutically acceptable salt or a prodrug thereof, is disclosed. Derivatives, salts and prodrugs are identified and described in detail. Methods of treating certain conditions or diseases, and compositions and medicaments related thereto are also contemplated. ... 12/07/06 - 20060276437 - Process for producing optically active dihydropyridinephosphonic ester characterized by comprising: dissolving a racemate of the compound of formula (1) in a solvent to prepare a supersaturated solution; and adding crystal of either one optically active substance of the compound of formula (1) as a seed crystal in the supersaturated solution to allow crystal of the one optically ... 11/30/06 - 20060270632 - 4-(2-furoyl) aminopiperidine compound useful as therapeutic agent for itching and pharmaceutically acceptable salts thereof. The compounds exhibit pruritus-inhibiting action, and are useful for prevention or treatment of itching and pruritus caused by reaction against insect-inflicted wounds, reaction against environmental allergens, skin infections or external parasite infections, or caused to renal dialysis patient. ... 10/26/06 - 20060241083 - Novel heteroaryl phosphonates as cardioprotective agents This invention teaches a-substituted phosphonates, their preparation, pharmaceutical compositions thereof, biologically acceptable salts thereof, and methods for treating various disorders using such compositions. ... 10/26/06 - 20060241082 - Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease Disclosed are compositions and methods for treating Parkinson's disease. ... 10/19/06 - 20060234984 - Mitotic kinesin inhibitors The present invention relates to dihydropyrrole compounds of Formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer ... 10/12/06 - 20060229280 - Endothelin antagonists or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin. ... 10/05/06 - 20060223784 - Method and compositions for temporarily incapacitating subjects A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds are rapidly metabolized to inactive and non-toxic metabolites when exposure to the modified compounds is halted. One ... 09/07/06 - 20060199787 - Compositions comprising oxophosphonate-based metalloproteinase inhibitors The present invention relates to compositions useful for treating or controlling disease states or conditions associated with zinc containing proteinases, especially metalloproteinases. The active ingredient in these compositions is an alpha-oxo- or alpha-thioxophosphonate of formula (I). Out of the phosphonates of formula (I), some are known and others are new. ... 08/17/06 - 20060183717 - Process for treating lameness with an osseous, articular or osteoarticular component in human or veterinary medicine, comprising the administration of a bisphosphonic acid derivative or R2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridylmethyl, a 1-pyridyl-1-hydroxymethyl, an imidazolylmethyl or a 4-thiomorpholinyl, of one of its pharmaceutically acceptable salts or of one of its hydrates. ... 07/27/06 - 20060166938 - Method of treatment using bisphosphonic acid The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficacious daily dose of a bisphosphonic acid or a pharmaceutically ... 07/27/06 - 20060166937 - Bisphosphonates for the treatment of atherosclerosis and device comprising them A method for the treatment of atherosclerosis, in particular atherosclerotic/valve calcification and plaque rupture/stroke, in a patient in need of such treatment, e.g. a patient with aterial or valve calcification, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient. ... 07/20/06 - 20060160771 - Aminophosphonic acid derivatives, addition salts thereof and sip receptor modulators and act as effective S1P receptor modulators while posing less side effects. ... 07/13/06 - 20060154898 - Diphosphonate solutions A pharmaceutical product containing pamidronate and other diphosphonate solutions in an appropriate container, a pH of between 5 and 8 and without organic acid buffer or polyethylen glycol. The container may be treated glass or made of other appropriate material. Coated elastomeric stoppers are also included. A method of producing ... 07/06/06 - 20060148763 - Compounds and methods for regulating triglyceride levels The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such ... 07/06/06 - 20060148762 - New crystalline form of the sodium salt of 3-pyridyl-1-hydroxyehtylidene-1,1-bisphosphonic acid The present invention relates to a crystalline, hydrated form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid. The hydrate contains from 6.4 up to 22 weight % of sodium and 15 up to 23 weight % of crystalline water if the sodium content is lower than 7.5 weight %, based on ... 06/29/06 - 20060142250 - Protein tyrosine phosphatase inhibitors and methods of use thereof The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions ... 06/29/06 - 20060142249 - Ophthalmic use The present invention relates to the use of a GABA-C-antagonist in the preparation of a medicament for the treatment of myopia. ... 06/15/06 - 20060128670 - Pesticidally active ketone and oxime derivatives Compounds of formula (I), wherein A0, A1, and A2 are each independently of the others a bond or a C1-C6alkylene bridge; A3 is a C1-C6alkylene bridge which is unsubstituted or substituted by from one to six identical or different substituents selected from halogen and C3-C8cycloalkyl; Y is, for example, 0, ... 05/18/06 - 20060105999 - Novel inhibitors of beta-lactamase The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel β-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic β-lactamase inhibitors presently available, and which do not require β-lactam pharmacophore. The invention also provides ... 05/18/06 - 20060105998 - Antiprotozoal ring-substiuted phospholipids Disclosed are novel ring containing phospholipids represented by the structural formula A-X—PO3—W and physiologically acceptable salts thereof and a process for the preparation of these compounds. The compounds can be used for the treatment of protozoal diseases and especially leishmaniasis. ... 04/27/06 - 20060089333 - Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents wherein A+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such ... 04/13/06 - 20060079487 - Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as Leishmania major farnesyl diphosphate synthase (FPPS) inhibition, Dictyostelium discoideum growth inhibition, human gamma delta T cell activation, and bone ... 03/30/06 - 20060069069 - Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses A composition is provided which contains calcium chelators, bisphosphonates, and/or citrate compounds and which may be used for treating and or reducing pathological calcifications, heavy metal poisoning, the growth of Nanobacterium Calcifying Nano-Particles and calcification-induced diseases in humans and animals. The method includes administering a therapeutic composition of calcium chelators, ... 03/30/06 - 20060069068 - Methods and compositions for the treatment of diseases characterized by pathological calcification Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and/or a combination of supportive agents and which may be used for treating and ... 03/30/06 - 20060069067 - Combination of an aromatase inhibitor with a bisphosphonate The present invention provides a combination for the treatment of a disease or condition which responds to aromatase inhibition, in particular a proliferative disease, especially a malignant disease such as breast cancer or similar soft tissue endocrine-sensitive cancer, most preferably breast cancer, comprising an aromatase inhibitor and a bisphosphonate for ... 03/09/06 - 20060052347 - Geranylgeranyl pyrophosphate synthase inhibitors The invention provides novel pyrophosphate synthase inhibitors of formula I as well as compositions comprising such inhibitors and methods for their use. ... 02/16/06 - 20060035864 - Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders The present invention includes use of an angiotensin-converting enzyme (ACE) inhibitor in combination with a vitamin B6 related compound for the treatment of diabetes and diabetic related disorders and in particular the treatment of diabetic hypertension. ... 02/16/06 - 20060035863 - Noncardiotoxic pharmaceutical compounds The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, cancer and gastrointestinal disorders. In particular, the present invention describes pharmaceutical compositions that mitigate life-threatening arrhythmias such as torsade de pointes. Torsade de ... 01/26/06 - 20060019929 - Combination therapies employing platelet aggregation drugs The present invention provides pharmaceutical compositions comprising a platelet aggregation inhibitor and a compound selected from pyridoxal-5′-phosphate, a pyridoxal-5′-phosphate related compound, or a pharmaceutically acceptable salt thereof. The invention also includes methods for using a platelet aggregation inhibitor and a compound selected from pyridoxal-5′-phosphate, a pyridoxal-5′-phosphate related compound, or a ... 12/29/05 - 20050288258 - Compounds, compositions and methods for treating or preventing viral infections and associated diseases Pyridine derivatives that exhibit antiviral activity are disclosed. ... 12/22/05 - 20050282783 - Modified phosphocalcic compound, injectable composition containing same The invention concerns a phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline ... 12/15/05 - 20050277621 - 8-(2-hydroxyphenoxy) octyldiethanolamine and salts thereof for delivery of active agents The present invention provides 8-(2-hydroxyphenoxy)octyldiethanolamine) and salts thereof, compositions containing the same and one or more active agents, and methods of administering active agents with the same. The delivery agents of the present invention are well suited for forming non-covalent mixtures with active agents for oral, intracolonic, pulmonary, and other ... 11/24/05 - 20050261251 - Antiviral agents and methods of treating viral infections The present invention relates to methods of treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP) and its prodrug forms and to pharmaceutical compositions comprising these compounds. ... 11/24/05 - 20050261250 - Compositions and methods for inhibiting bone resorption Disclosed are compositions and methods for preventing, inhibiting, reducing and treating conditions and diseases associated with abnormal bone resorption in mammals, including for example osteoporosis. Embodiments of compositions of the invention comprise a pharmaceutically effective amount of alendronate and vitamin D3 suitable for once-weekly dosing. Compositions and methods of the ... 11/17/05 - 20050256090 - Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes wherein n is an integer of 0 to 3, or a pharmacologically acceptable salt thereof. ... 11/17/05 - 20050256089 - Phenyl-substituted 4-hydroxy-tetrahydropyridones to a plurality of processes for their preparation and to their use as pesticides and herbicides. ... 11/17/05 - 20050256088 - Pharmaceutical nitrones Pharmaceutical nitrone comprise condensates of an N-hydroxylamine and a physiological aldehyde, providing improved delivery and absorption, enhanced stability and reduced toxicity. Preferred physiological aldehydes are subject to endogenous cellular uptake transport, and include pyridoxal, pyridoxal phosphate, and heme-A. Essentially any physiologically compatible and pharmaceutically active hydroxylamine moiety may be incorporated, ... 09/29/05 - 20050215528 - Gnrh agonist combination drugs In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from ... 08/18/05 - 20050182028 - Pharmaceutical formulation for oral delivery of bisphosphates The present invention discloses a method for treating or preventing a bone disorder in a mammal in need thereof comprising orally administering to said mammal a pharmaceutically effective amount of a pharmaceutical composition of at least one bisphosphonate, or a pharmaceutically acceptable salt or esters thereof, and at least one ... 08/18/05 - 20050182027 - Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts The invention provides a series of lipophilic phosphonium cations (PhCs) labeled with 18F for non-invasive assessment of Δψm, lipophilic ammonium cation analogs of the PhCs, and methods of using same for imaging and detection of mitochondrial-related pathologies in patients using PET or SPECT. ... 08/11/05 - 20050176685 - Method for inhibiting bone resorption with an alendronate and vitamin d formulation Composition and method for preventing or treating abnormal bone resorption in mammals, the composition characterized as containing, a supplementary effective amount of a non-activated metabolite of vitamin D2 and/or D3 and a pharmaceutically effective amount of bisphosphonate to provide vitamin D nutrition during treatment to facilitate normal bone formation and ... 08/04/05 - 20050171062 - Treatment of inflammatory bowel disease or derivatives thereof, as defined in the specification or pharmaceutically acceptable salts or prodrugs thereof. ... 07/28/05 - 20050164990 - Piperidinyl prostaglandin e analogs wherein X, Y, Z, D and R3 are as defined in the specification. ... 07/28/05 - 20050164989 - Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative wherein, for example, A is a hydrogen atom or a substituent such as a lower alkyl group or the like; W, X, Y and Z are independently a hydrogen atom or a substituent such as a lower alkyl group, aryl group, arylacyl group, arylaminocarbonyl group or the like; and Q ... 07/14/05 - 20050153937 - Desensitization of compliment activation using monocyte/macrophage inhibitory compounds The present invention relates to methods and compositions designed for the prevention, reduction, treatment, or management of complement activation-related acute hypersensitivity also known as C-mediated pseudoallergy (CARPA) that results from the administration of a medicinal composition including, but not limited to, those compositions in liposomal, micellar, nanoparticle, emulsion, and colloidal ... 06/30/05 - 20050143349 - Phosphorus containing compounds useful for the regulation of ldl and lp(a) levels B1, B2, B3, B4, Ar, F, E, G, Y1, Y2, Y3, X, U, V, R4, R5, Q, D, n, Het, Z1, and Z2, are as defined herein. ... 06/30/05 - 20050143348 - Doxepin analogs and methods of use thereof The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof. ... 06/09/05 - 20050124586 - Alpha-substituted arylalkyl phosphonate derivatives The present invention relates to novel α-substituted arylalkylphosphonate derivatives and their uses for lowering plasma levels of apo (a), Lp(a), apo B, apo B associated lipoproteins (low density lipoproteins and very low density lipoproteins) and for lowering plasma levels of total cholesterol. ... 06/02/05 - 20050119230 - Pharmaceutical products comprising bisphosphonated A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a ... 06/02/05 - 20050119229 - Fungicidal mixtures based on prothioconazole and containing an insecticide in a synergistically effective amount is described. ... ### FreshPatents.com Support |